Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now central to managing type 2 diabetes and obesity, with growing potential in cardiovascular, kidney, and neurodegenerative diseases like Parkinson’s. As their use expands, concerns about ocular safety have emerged. These concerns began with the SUSTAIN-6 trial, which linked semaglutide to
9542 Reached72 Comments1 Likes
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Pancytopenia, a rare presentation of hyperthyroidism
830 Reached2 Comments
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes
Complicated case of Osteoarthritis
1849 Reached2 Comments3 Likes